Why is Caixabank stock climbing today?

InnovAge (INNV) shares fell 9.4% in pre-market trading after pricing a 10M share secondary offering at $9.25/share. Jaguar Health (JAGX) dropped 28% after a 1,190% gain the prior day. Voyager (VOYG) declined 6% following a $350M convertible note offering. Other stocks like RML, SBSW, and AU also fell.

Greenland Mines Ltd (GRML) surged 30.39% after securing a major mining license. The company's stock has seen significant volatility, closing at $9.42 on September 21, 2026, and spiking to $18.21 on September 22 before settling near $14.15. GRML is an early-stage miner with negative earnings but strong liquidity. The company controls the Sarfartoq Nd-Pr rare earth project and the Skaergaard PGM–vanadium asset, benefiting from a U.S.–Denmark–Greenland security pact.

Maze Therapeutics (MAZE) stock rose 2.9% in pre-market trading after CIBC initiated coverage with an Outperformer rating and a $50 price target. The company has 13 buy-equivalent ratings. Vertex Pharmaceuticals' (VRTX) positive kidney disease data also boosted MAZE, as both companies work on APOL1 inhibitors. The S&P 500, Dow, and Nasdaq showed little movement, indicating the rally was driven by company-specific news.

Meta launched Muse, an AI agent for everyday tasks, gaining 2.5M U.S. downloads. It can book travel, shop, and handle emails. Amazon blocked Muse, citing unauthorized access, while Shopify partnered with it. Meta's shares rose 10% on Monday. Analysts note Muse's success may depend on expanding capabilities and user trust. According to Sensor Tower, Muse is the top free app in Apple's App Store.

Moderna (MRNA) closed at $182.56, up 5.56%, after hitting a 52-week high of $187.20. The rally follows strong Phase 3 results for its melanoma vaccine, developed with Merck. Analysts have raised targets, with Wolfe Research estimating peak sales of $9.2B for its cancer platform. Moderna priced a $2.6B convertible notes offering and received FDA approvals for new vaccines. The stock's support is around $168–$172, with resistance near $187.

Stifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained Azure growth, OpenAI contributions, and improved efficiency. Analysts expect mid-to-upper-teens revenue growth, offsetting moderating seat growth. Stifel revised earlier margin concerns due to Azure efficiency gains and reduced OpenAI payments.